Life Science Investment Leader Michael Ryan Joins Sigyn Therapeutics Board Amid Blood Purification Tech Development
The appointment of Michael Ryan, founder of Ireland's largest angel investment syndicate, to Sigyn Therapeutics' Board of Directors strengthens the company's position in developing crucial blood purification technologies for treating life-threatening conditions.
Sigyn Therapeutics (OTCQB: SIGY) has appointed Michael Ryan, a prominent figure in life science investment and technology, to its Board of Directors. Ryan brings substantial expertise as the Founding Director of Irrus Investments, Ltd., Ireland's largest angel investment syndicate, which has invested over $50 million in early-stage life science and technology companies across Ireland, UK, Sweden, and the United States.
The appointment comes at a critical time as Sigyn advances its blood purification technology, Sigyn Therapy, which has shown promise in reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. This technology could potentially address major global health challenges, including antibiotic-resistant bacterial infections, endotoxemia, and sepsis - the leading cause of death in U.S. hospitals.
Ryan's track record includes successful leadership roles as CEO of Sedana Medical until its listing on Stockholm's First North stock exchange in 2017, and as CEO of Artema Medical AB, where he guided the company through its acquisition by Datascope Corporation. His expertise could prove valuable as Sigyn works to commercialize its technology and expand its oncology pipeline.
The significance of this appointment extends beyond corporate governance. With the global rise in antibiotic-resistant infections and the persistent challenge of sepsis in healthcare settings, Ryan's experience could help accelerate the development and deployment of Sigyn's blood purification technologies. The company's focus on enhancing cancer therapies and addressing drug-resistant infections positions it at the intersection of several critical healthcare challenges, with potential implications for both the dialysis and biopharmaceutical industries.